TransMedics Group, Inc. (TMDX) Return on Invested Capital (ROIC): 10.94%
Is TransMedics Group, Inc.’s return on invested capital (ROIC) high or low?
TransMedics Group, Inc.'s return on invested capital (ROIC) of 10.94% is 220% above its 5-year average of -9.11%, near the high end of its 5-year range (-35.31%–10.94%).
As of Saturday, June 20, 2026. 37.44% above its 12-month average of 7.96%.
TMDX Return on Invested Capital (ROIC) Chart
TMDX Average Return on Invested Capital (ROIC) Chart
TMDX Current vs Average Return on Invested Capital (ROIC) Chart
TMDX Return on Invested Capital (ROIC) Metrics
RETURN ON INVESTED CAPITAL (ROIC)
10.94%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
7.96%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-0.14%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-9.11%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
+37.44%
CURRENT VS 3Y AVG
+8203.70%
CURRENT VS 5Y AVG
+220.04%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
TMDX Competitors' Return on Invested Capital (ROIC)
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TransMedics Group, Inc. (TMDX) | $2.72B | 10.94% | 7.96% | -0.14% | -9.11% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.07B | 5.67% | -6.15% | -6.50% | -3.41% |
| 23andMe Holding Co. (ME)vs › | $15.31M | -553.10% | -332.89% | -182.55% | -143.76% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.64B | 2.04% | 2.21% | 2.35% | 2.39% |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.91B | 6.02% | 9.35% | -2.77% | -9.72% |
| Tempus AI, Inc. (TEM)vs › | $8.87B | -10.29% | -59.01% | -58.33% | -53.58% |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.91B | 8.36% | 4.65% | 6.09% | 6.66% |
| Baxter International Inc. (BAX)vs › | $10.27B | -1.79% | -0.86% | -2.61% | 0.30% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | -24.28% | -15.13% | -6.38% | -2.73% |
| Revvity, Inc. (RVTY)vs › | $11.16B | 2.82% | 2.97% | 3.42% | 5.50% |
Capital Efficiency
ROIC
10.9%
ROE
34.8%
TransMedics Group, Inc. Return on Invested Capital (ROIC) Formula & Definition
ROIC = NOPAT / Invested Capital
Return on invested capital measures the after-tax return a company earns on all capital (debt and equity) invested in the business.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
TransMedics Group, Inc. Return on Invested Capital (ROIC) FAQ
- What is the return on invested capital (ROIC) for TransMedics Group, Inc. (TMDX)?
- The return on invested capital (ROIC) for TMDX stock is 10.94%.
- Is TransMedics Group, Inc.'s return on invested capital (ROIC) high or low?
- TransMedics Group, Inc.'s return on invested capital (ROIC) of 10.94% is 220% above its 5-year average of -9.11%, near the high end of its 5-year range (-35.31%–10.94%).
- What is the TTM average return on invested capital (ROIC) for TransMedics Group, Inc. (TMDX)?
- The TTM average return on invested capital (ROIC) for TMDX stock is 7.96%.
- What is the 3Y average return on invested capital (ROIC) for TransMedics Group, Inc. (TMDX)?
- The 3Y average return on invested capital (ROIC) for TMDX stock is -0.14%.
- What is the 5Y average return on invested capital (ROIC) for TransMedics Group, Inc. (TMDX)?
- The 5Y average return on invested capital (ROIC) for TMDX stock is -9.11%.
TransMedics Group, Inc. Return on Invested Capital (ROIC) History
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2025-12-31 | 10.94% |
| 2024-12-31 | 4.98% |
| 2023-12-31 | -4.13% |
| 2022-12-31 | -12.33% |
| 2021-12-31 | -35.31% |
| 2020-12-31 | -18.83% |
| 2019-12-31 | -33.19% |
| 2018-12-31 | -68.36% |
| 2017-12-31 | -73.19% |
| 2016-12-31 | -47.26% |
Related Metrics
About TransMedics Group, Inc.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Waleed H. Hassanein